{
  "run": {
    "id": "cmnr13ufq0407p6583wpzkdgt",
    "region": "US",
    "assetId": "cmnr13uet0400p658oylulqni",
    "ticker": "GL",
    "snapshotId": "cmnr13uf80403p658zhk5jnxr",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:20:49.620Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr13uf80403p658zhk5jnxr",
      "assetId": "cmnr13uet0400p658oylulqni",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 147.85,
          "dayLow": 145.375,
          "volume": 329464,
          "dayHigh": 148.23,
          "currency": "USD",
          "prevClose": 143.74,
          "week52Low": 110.75,
          "week52High": 152.71
        },
        "fundamentals": {
          "pe": 9.80098107918711,
          "beta": 0.683596724498021,
          "epsTTM": 14.27,
          "fcfTTM": 1281130000,
          "growth": {
            "epsYoy": 0.1901584653878231,
            "revenueYoy": 0.03742582513292936
          },
          "sector": "Life Insurance",
          "margins": {
            "net": 0.208185064384052,
            "gross": 0.2605113208882464,
            "operating": 0.2632363318302028
          },
          "website": "http://globelifeinsurance.com",
          "industry": "Life insurance",
          "pegRatio": 0.515411241839708,
          "ebitdaTTM": 1508366000,
          "forwardPe": 9.21343873517787,
          "marketCap": 10000000000,
          "totalCash": 144704000,
          "totalDebt": 2625449000,
          "debtEquity": 0.439436653193472,
          "quickRatio": null,
          "revenueTTM": 1455407000,
          "companyName": "GLOBE LIFE INC.",
          "priceToBook": 1.90496527733586,
          "currentRatio": null,
          "dividendYield": 0.00766823626569541,
          "returnOnAssets": 0.009833096274214722,
          "returnOnEquity": 0.194363150943355,
          "analystOpinions": null,
          "businessSummary": "Globe Life Inc. (GL) is an American financial services holding company listed on the New York Stock Exchange which operates through its wholly owned subsidiaries providing life insurance, annuity, and supplemental health insurance products. The company is based in McKinney, Texas.",
          "enterpriseValue": 13862110541.7,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 3732,
          "sharesOutstanding": 78637130,
          "enterpriseToEbitda": 9.1901504951053,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 9.524559481780699,
          "operatingCashflowTTM": 1396391000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:20:49.604Z"
    },
    "results": [
      {
        "id": "cmnr13uft040bp6582cwjxvqk",
        "runId": "cmnr13ufq0407p6583wpzkdgt",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GL\",\"currency\":\"USD\",\"current_price\":147.85,\"target_price_6m\":153.0,\"target_price_12m\":160.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Low P/E of 9.8x and PEG of 0.52 signal undervaluation relative to growth.\",\"Strong ROE of 19.4% supports earnings compounding at current book levels.\",\"EPS grew 19% YoY demonstrating operating leverage in the insurance model.\",\"Robust FCF of $1.28B provides ample capital return and deleveraging capacity.\",\"Stock near 52-week high limits near-term upside; short-seller overhang persists.\"],\"key_drivers\":[{\"driver\":\"Life insurance premium growth driven by direct-to-consumer distribution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin stability above 26% supports earnings power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Share buybacks funded by strong FCF enhance EPS growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low beta (0.68) offers defensive positioning in volatile markets\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Lingering reputational risk from past short-seller fraud allegations\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Rising interest rates could pressure bond portfolio mark-to-market\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Modest revenue growth of 3.7% YoY limits topline re-rating\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Debt/equity of 0.44x manageable but constrains financial flexibility\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Regulatory or legal escalation from short-seller fraud allegations could materially impair valuation.\",\"Unexpected claims experience deterioration in life or supplemental health lines.\",\"Interest rate volatility impacts investment income and unrealized bond losses.\",\"Competitive pressure in supplemental health and direct-to-consumer life insurance.\",\"Key-man or distribution channel concentration risk in agency force.\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.26,\"wacc\":0.10,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":125.0,\"prob\":0.15,\"notes\":\"Fraud allegations gain traction or regulatory action compresses multiple to 8x.\"},\"base\":{\"target_price\":160.0,\"prob\":0.60,\"notes\":\"Steady ~10% EPS growth with P/E holding near 10-10.5x on cleared overhang.\"},\"bull\":{\"target_price\":185.0,\"prob\":0.25,\"notes\":\"Multiple re-rates to 12x as allegations fully dismissed and buybacks accelerate EPS.\"}},\"method_notes\":\"Earnings-power valuation: FY+1 EPS ~$15.60 (9% growth) x 10.5x target P/E = $164 rounded to $160 base. Insurance-specific focus on ROE sustainability (19.4%), premium growth (~4% CAGR), and margin stability. PEG of 0.52 supports undervaluation thesis but tempered by reputational risk overhang and proximity to 52-week high. Probability-weighted scenario value ~$161 aligns with 12M target. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Regulatory or legal escalation from short-seller fraud allegations could materially impair valuation.",
            "Unexpected claims experience deterioration in life or supplemental health lines.",
            "Interest rate volatility impacts investment income and unrealized bond losses.",
            "Competitive pressure in supplemental health and direct-to-consumer life insurance.",
            "Key-man or distribution channel concentration risk in agency force."
          ],
          "ticker": "GL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady ~10% EPS growth with P/E holding near 10-10.5x on cleared overhang.",
              "target_price": 160
            },
            "bear": {
              "prob": 0.15,
              "notes": "Fraud allegations gain traction or regulatory action compresses multiple to 8x.",
              "target_price": 125
            },
            "bull": {
              "prob": 0.25,
              "notes": "Multiple re-rates to 12x as allegations fully dismissed and buybacks accelerate EPS.",
              "target_price": 185
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.1,
            "revenue_cagr_3y": 0.04,
            "terminal_multiple": 10.5,
            "ebit_margin_target": 0.26
          },
          "key_drivers": [
            {
              "driver": "Life insurance premium growth driven by direct-to-consumer distribution",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Operating margin stability above 26% supports earnings power",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Share buybacks funded by strong FCF enhance EPS growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Low beta (0.68) offers defensive positioning in volatile markets",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Lingering reputational risk from past short-seller fraud allegations",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Rising interest rates could pressure bond portfolio mark-to-market",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Modest revenue growth of 3.7% YoY limits topline re-rating",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Debt/equity of 0.44x manageable but constrains financial flexibility",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Earnings-power valuation: FY+1 EPS ~$15.60 (9% growth) x 10.5x target P/E = $164 rounded to $160 base. Insurance-specific focus on ROE sustainability (19.4%), premium growth (~4% CAGR), and margin stability. PEG of 0.52 supports undervaluation thesis but tempered by reputational risk overhang and proximity to 52-week high. Probability-weighted scenario value ~$161 aligns with 12M target. Not investment advice.",
          "current_price": 147.85,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Low P/E of 9.8x and PEG of 0.52 signal undervaluation relative to growth.",
            "Strong ROE of 19.4% supports earnings compounding at current book levels.",
            "EPS grew 19% YoY demonstrating operating leverage in the insurance model.",
            "Robust FCF of $1.28B provides ample capital return and deleveraging capacity.",
            "Stock near 52-week high limits near-term upside; short-seller overhang persists."
          ],
          "target_price_6m": 153,
          "target_price_12m": 160
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 38647,
        "createdAt": "2026-04-09T05:20:49.620Z",
        "usage": {
          "inputTokens": 3556,
          "outputTokens": 1698,
          "costUsd": 0.06023
        }
      },
      {
        "id": "cmnr13uft040ep6586le57ah5",
        "runId": "cmnr13ufq0407p6583wpzkdgt",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"EquityResearchAnalyst\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"GL\",\n  \"currency\": \"USD\",\n  \"current_price\": 147.85,\n  \"target_price_6m\": 150.0,\n  \"target_price_12m\": 155.0,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\"Stable premium growth in life insurance sector\", \"Strong earnings growth from margin expansion\", \"Low debt levels support financial stability\", \"Competitive pressures may limit pricing power\", \"Valuation appears fair relative to peers\"],\n  \"key_drivers\": [\n    {\"driver\": \"Premium Growth\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Investment Income\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Expense Ratio\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n    {\"driver\": \"Regulatory Changes\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Interest Rates\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Mortality Experience\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n    {\"driver\": \"Competition\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Economic Conditions\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n  ],\n  \"risks\": [\"Interest rate volatility\", \"Increased mortality claims\", \"Regulatory changes\", \"Economic downturn\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.04,\n    \"ebit_margin_target\": 0.26,\n    \"wacc\": 0.07,\n    \"terminal_multiple\": 9.5\n  },\n  \"scenarios\": {\n    \"bear\": {\"target_price\": 140.0, \"prob\": 0.3, \"notes\": \"Lower growth and multiple compression.\"},\n    \"base\": {\"target_price\": 155.0, \"prob\": 0.5, \"notes\": \"Steady earnings and stable valuation.\"},\n    \"bull\": {\"target_price\": 170.0, \"prob\": 0.2, \"notes\": \"Accelerated growth and multiple expansion.\"}\n  },\n  \"method_notes\": \"Valuation based on earnings growth and P/E multiple. Recommendation reflects fair valuation with moderate upside. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "EquityResearchAnalyst",
          "risks": [
            "Interest rate volatility",
            "Increased mortality claims",
            "Regulatory changes",
            "Economic downturn"
          ],
          "ticker": "GL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady earnings and stable valuation.",
              "target_price": 155
            },
            "bear": {
              "prob": 0.3,
              "notes": "Lower growth and multiple compression.",
              "target_price": 140
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated growth and multiple expansion.",
              "target_price": 170
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.07,
            "revenue_cagr_3y": 0.04,
            "terminal_multiple": 9.5,
            "ebit_margin_target": 0.26
          },
          "key_drivers": [
            {
              "driver": "Premium Growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Investment Income",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Expense Ratio",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory Changes",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Interest Rates",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Mortality Experience",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Competition",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Economic Conditions",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on earnings growth and P/E multiple. Recommendation reflects fair valuation with moderate upside. Not investment advice.",
          "current_price": 147.85,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Stable premium growth in life insurance sector",
            "Strong earnings growth from margin expansion",
            "Low debt levels support financial stability",
            "Competitive pressures may limit pricing power",
            "Valuation appears fair relative to peers"
          ],
          "target_price_6m": 150,
          "target_price_12m": 155
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 335,
        "createdAt": "2026-04-09T05:20:49.620Z",
        "usage": {
          "inputTokens": 2071,
          "outputTokens": 3566,
          "costUsd": 0.002078
        }
      },
      {
        "id": "cmnr13uft040cp658m5v9fiu6",
        "runId": "cmnr13ufq0407p6583wpzkdgt",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Equity Research Analyst AI\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"GL\",\n  \"currency\": \"USD\",\n  \"current_price\": 147.85,\n  \"target_price_6m\": 162.00,\n  \"target_price_12m\": 176.00,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.72,\n  \"thesis_bullets\": [\n    \"Compelling valuation with a forward P/E under 10x and PEG of 0.52.\",\n    \"Consistent double-digit EPS growth driven by disciplined underwriting and buybacks.\",\n    \"High ROE of 19.4% demonstrates superior capital allocation and profitability.\",\n    \"Strong niche position in the middle-income life and health insurance market.\",\n    \"FCF generation supports continued dividend growth and aggressive share repurchases.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Life insurance premium growth\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Net investment income yield\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Share repurchase program execution\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Supplemental health product demand\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Operating margin efficiency\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Agent force productivity\",\n      \"impact\": \"LOW\",\n      \"direction\": \"POS\"\n    }\n  ],\n  \"risks\": [\n    \"Regulatory scrutiny on sales practices and distribution channels.\",\n    \"Adverse mortality experience trends impacting life insurance claims.\",\n    \"Significant decline in interest rates reducing reinvestment yields.\",\n    \"Credit defaults within the fixed-income investment portfolio.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.045,\n    \"ebit_margin_target\": 0.27,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 10.5\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 130.00,\n      \"prob\": 0.2,\n      \"notes\": \"Regulatory headwinds or mortality spikes lead to multiple compression.\"\n    },\n    \"base\": {\n      \"target_price\": 176.00,\n      \"prob\": 0.6,\n      \"notes\": \"Steady premium growth and continued share buybacks drive EPS.\"\n    },\n    \"bull\": {\n      \"target_price\": 195.00,\n      \"prob\": 0.2,\n      \"notes\": \"Higher interest rates and robust sales growth expand the P/E multiple.\"\n    }\n  },\n  \"method_notes\": \"Valuation derived from a 11x forward P/E multiple on projected EPS. Recommendation reflects ~19% upside, supported by strong ROE and low PEG. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Equity Research Analyst AI",
          "risks": [
            "Regulatory scrutiny on sales practices and distribution channels.",
            "Adverse mortality experience trends impacting life insurance claims.",
            "Significant decline in interest rates reducing reinvestment yields.",
            "Credit defaults within the fixed-income investment portfolio."
          ],
          "ticker": "GL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady premium growth and continued share buybacks drive EPS.",
              "target_price": 176
            },
            "bear": {
              "prob": 0.2,
              "notes": "Regulatory headwinds or mortality spikes lead to multiple compression.",
              "target_price": 130
            },
            "bull": {
              "prob": 0.2,
              "notes": "Higher interest rates and robust sales growth expand the P/E multiple.",
              "target_price": 195
            }
          },
          "confidence": 0.72,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.045,
            "terminal_multiple": 10.5,
            "ebit_margin_target": 0.27
          },
          "key_drivers": [
            {
              "driver": "Life insurance premium growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Net investment income yield",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Share repurchase program execution",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Supplemental health product demand",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Operating margin efficiency",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Agent force productivity",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation derived from a 11x forward P/E multiple on projected EPS. Recommendation reflects ~19% upside, supported by strong ROE and low PEG. Not investment advice.",
          "current_price": 147.85,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Compelling valuation with a forward P/E under 10x and PEG of 0.52.",
            "Consistent double-digit EPS growth driven by disciplined underwriting and buybacks.",
            "High ROE of 19.4% demonstrates superior capital allocation and profitability.",
            "Strong niche position in the middle-income life and health insurance market.",
            "FCF generation supports continued dividend growth and aggressive share repurchases."
          ],
          "target_price_6m": 162,
          "target_price_12m": 176
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 11647,
        "createdAt": "2026-04-09T05:20:49.620Z",
        "usage": {
          "inputTokens": 2411,
          "outputTokens": 792,
          "costUsd": 0.014326
        }
      },
      {
        "id": "cmnr13uft040ap6581wjcjuen",
        "runId": "cmnr13ufq0407p6583wpzkdgt",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GL\",\"currency\":\"USD\",\"current_price\":147.85,\"target_price_6m\":152.5,\"target_price_12m\":154,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Single-digit earnings multiple discounts regulatory and litigation uncertainty.\",\"High ROE and steady cash generation support intrinsic value and buybacks.\",\"Revenue growth is modest, limiting rerating without cleaner legal visibility.\",\"Defensive life and supplemental products should sustain resilient earnings.\",\"Risk/reward looks balanced after shares approach 52-week highs.\"],\"key_drivers\":[{\"driver\":\"Low valuation vs ROE\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Buybacks and capital return\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Supplemental health demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Interest income and spreads\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Litigation/regulatory overhang\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Mortality and reserve volatility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Agent productivity and retention\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Persistency and lapse trends\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Ongoing litigation or investigations could compress valuation.\",\"Agent productivity weakness could slow premium growth.\",\"Mortality, morbidity, or reserve changes could pressure earnings.\",\"Rate declines could reduce investment income.\",\"Capital or regulatory changes could limit buybacks.\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.26,\"wacc\":0.095,\"terminal_multiple\":9.8},\"scenarios\":{\"bear\":{\"target_price\":128,\"prob\":0.25,\"notes\":\"Legal overhang persists and growth slows, keeping valuation compressed.\"},\"base\":{\"target_price\":154,\"prob\":0.5,\"notes\":\"Steady earnings and buybacks offset modest top-line growth.\"},\"bull\":{\"target_price\":171,\"prob\":0.25,\"notes\":\"Overhang eases and shares rerate on durable ROE and capital return.\"}},\"method_notes\":\"Base case uses earnings-power and P/B cross-checks from snapshot fundamentals; fair value implies only modest 12M upside, so HOLD. Snapshot quote fields were kept authoritative and not overridden. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Model Recommendation v2",
          "risks": [
            "Ongoing litigation or investigations could compress valuation.",
            "Agent productivity weakness could slow premium growth.",
            "Mortality, morbidity, or reserve changes could pressure earnings.",
            "Rate declines could reduce investment income.",
            "Capital or regulatory changes could limit buybacks."
          ],
          "ticker": "GL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady earnings and buybacks offset modest top-line growth.",
              "target_price": 154
            },
            "bear": {
              "prob": 0.25,
              "notes": "Legal overhang persists and growth slows, keeping valuation compressed.",
              "target_price": 128
            },
            "bull": {
              "prob": 0.25,
              "notes": "Overhang eases and shares rerate on durable ROE and capital return.",
              "target_price": 171
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.04,
            "terminal_multiple": 9.8,
            "ebit_margin_target": 0.26
          },
          "key_drivers": [
            {
              "driver": "Low valuation vs ROE",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Buybacks and capital return",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Supplemental health demand",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Interest income and spreads",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Litigation/regulatory overhang",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Mortality and reserve volatility",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Agent productivity and retention",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Persistency and lapse trends",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Base case uses earnings-power and P/B cross-checks from snapshot fundamentals; fair value implies only modest 12M upside, so HOLD. Snapshot quote fields were kept authoritative and not overridden. not investment advice",
          "current_price": 147.85,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Single-digit earnings multiple discounts regulatory and litigation uncertainty.",
            "High ROE and steady cash generation support intrinsic value and buybacks.",
            "Revenue growth is modest, limiting rerating without cleaner legal visibility.",
            "Defensive life and supplemental products should sustain resilient earnings.",
            "Risk/reward looks balanced after shares approach 52-week highs."
          ],
          "target_price_6m": 152.5,
          "target_price_12m": 154
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0f5ad5105af98eb30069d759685fc48190a879adacbfed80ce",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 32402,
        "createdAt": "2026-04-09T05:20:49.620Z",
        "usage": {
          "inputTokens": 2345,
          "outputTokens": 1819,
          "costUsd": 0.02957
        }
      },
      {
        "id": "cmnr13uft040dp658q7hq3ltt",
        "runId": "cmnr13ufq0407p6583wpzkdgt",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Analyst\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"GL\",\n  \"currency\": \"USD\",\n  \"current_price\": 147.85,\n  \"target_price_6m\": 160,\n  \"target_price_12m\": 172,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Trades at discounted 9.2x forward P/E with PEG 0.5\",\n    \"Strong 19% ROE and EPS growth drive shareholder value\",\n    \"Stable cash flows fund dividends and ongoing buybacks\",\n    \"Low-beta defensive play in uncertain economic environment\",\n    \"Mixed revenue growth tempered by solid underwriting margins\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Forward P/E valuation\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"EPS and ROE trends\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Revenue growth rate\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Investment portfolio yields\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Share repurchases\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Regulatory changes\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Macroeconomic conditions\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Dividend consistency\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    }\n  ],\n  \"risks\": [\n    \"Recession reducing new policy sales\",\n    \"Interest rate volatility on portfolio\",\n    \"Increased insurance sector regulation\",\n    \"Competition from larger peers\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.05,\n    \"ebit_margin_target\": 0.27,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 10.5\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 128,\n      \"prob\": 0.3,\n      \"notes\": \"Weak growth and higher claims pressure multiples.\"\n    },\n    \"base\": {\n      \"target_price\": 172,\n      \"prob\": 0.5,\n      \"notes\": \"Steady execution on trends with modest multiple expansion.\"\n    },\n    \"bull\": {\n      \"target_price\": 195,\n      \"prob\": 0.2,\n      \"notes\": \"Accelerated EPS growth and P/E re-rating higher.\"\n    }\n  },\n  \"method_notes\": \"Forward P/E and Gordon growth with 5% rev CAGR, 27% EBIT margin, 8.5% WACC, 10.5x terminal. 16% 12M upside supports BUY per rubric. Consensus not used for targets. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Analyst",
          "risks": [
            "Recession reducing new policy sales",
            "Interest rate volatility on portfolio",
            "Increased insurance sector regulation",
            "Competition from larger peers"
          ],
          "ticker": "GL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady execution on trends with modest multiple expansion.",
              "target_price": 172
            },
            "bear": {
              "prob": 0.3,
              "notes": "Weak growth and higher claims pressure multiples.",
              "target_price": 128
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated EPS growth and P/E re-rating higher.",
              "target_price": 195
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 10.5,
            "ebit_margin_target": 0.27
          },
          "key_drivers": [
            {
              "driver": "Forward P/E valuation",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "EPS and ROE trends",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Revenue growth rate",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Investment portfolio yields",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Share repurchases",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Regulatory changes",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Macroeconomic conditions",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Dividend consistency",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "Forward P/E and Gordon growth with 5% rev CAGR, 27% EBIT margin, 8.5% WACC, 10.5x terminal. 16% 12M upside supports BUY per rubric. Consensus not used for targets. Not investment advice.",
          "current_price": 147.85,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Trades at discounted 9.2x forward P/E with PEG 0.5",
            "Strong 19% ROE and EPS growth drive shareholder value",
            "Stable cash flows fund dividends and ongoing buybacks",
            "Low-beta defensive play in uncertain economic environment",
            "Mixed revenue growth tempered by solid underwriting margins"
          ],
          "target_price_6m": 160,
          "target_price_12m": 172
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "d0f188ac-5b9a-97e5-a923-cc0e95216b21",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 19467,
        "createdAt": "2026-04-09T05:20:49.620Z",
        "usage": {
          "inputTokens": 2684,
          "outputTokens": 3078,
          "costUsd": 0.054222
        }
      }
    ]
  }
}